Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer



Prostate cancer has many treatment methods. And yet, most researchers agree that improvement is required. Prevention of prostate cancer is a bigger challenge. The current technology utilizes a co-targeting aptamer against EGFR and survivin against prostate cancer. Early data suggests high induction of apoptosis in vitro and in vivo. We would like to move this drug beyond the C4-2 PCa xenograft model. Co-delivery of two siRNAs in one chimera with bivalent aptamers represents a novel approach for combination therapy using siRNA molecules. Our design has the potential as a platform technology for advancing RNAi therapeutics.


AURI #2017-006

Patent Information:
For Information, Contact:
Carl Clark
Director Technology Transfer
Augusta University
Hong Liu
© 2018. All Rights Reserved. Powered by Inteum